Drugs / Measles, mumps, and rubella vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06397768 Background | May 2024 → Sep 2025 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps, and rubella vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06397768 ↗ |
| Modality | Vaccine | “Measles, mumps, and rubella vaccine” NCT06397768 ↗ |
| Route | Intramuscular | “Route of administration:Subcutaneous or Intramuscular” NCT06397768 ↗ |
| Route | Subcutaneous | “Route of administration:Subcutaneous or Intramuscular” NCT06397768 ↗ |